Global Left Atrial Appendage (LAA) Closure Market Growth (Status and Outlook) 2023-2029

Global Left Atrial Appendage (LAA) Closure Market Growth (Status and Outlook) 2023-2029

Left atrial appendage closure (LAAC) is a treatment strategy to reduce the risk of left atrial appendage blood clots from entering the bloodstream and causing a stroke in patients with non-valvular atrial fibrillation (AF).

LPI (LP Information)' newest research report, the “Left Atrial Appendage (LAA) Closure Industry Forecast” looks at past sales and reviews total world Left Atrial Appendage (LAA) Closure sales in 2022, providing a comprehensive analysis by region and market sector of projected Left Atrial Appendage (LAA) Closure sales for 2023 through 2029. With Left Atrial Appendage (LAA) Closure sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Left Atrial Appendage (LAA) Closure industry.

This Insight Report provides a comprehensive analysis of the global Left Atrial Appendage (LAA) Closure landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Left Atrial Appendage (LAA) Closure portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Left Atrial Appendage (LAA) Closure market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Left Atrial Appendage (LAA) Closure and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Left Atrial Appendage (LAA) Closure.

The global Left Atrial Appendage (LAA) Closure market size is projected to grow from US$ 240.5 million in 2022 to US$ 695.7 million in 2029; it is expected to grow at a CAGR of 16.4% from 2023 to 2029.

On March 13, 2015, the U.S. Food and Drug Administration approved the WATCHMAN™ LAAC Implant, from Boston Scientific, to reduce the risk of thromboembolism from the left atrial appendage in patients with non-valvular AF who are at increased risk of stroke and are recommended for blood thinning medicines, are suitable for warfarin and have an appropriate reason to seek a non-drug alternative to warfarin. The Watchman implant was studied in two randomized clinical trials and several clinical registries. The implant was approved in Europe in 2009.

This report presents a comprehensive overview, market shares, and growth opportunities of Left Atrial Appendage (LAA) Closure market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Epicardial LAA Closure Device
Endocardial LAA Closure Device

Segmentation by application
Hospitals
ASCs
Specialty Clinic

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AtriCure
Boston Scientific
Coherex Medical
Abbott
Occlutech
Lifetech Scientific
SentreHEART

Please note: The report will take approximately 2 business days to prepare and deliver.